<DOC>
	<DOC>NCT00410163</DOC>
	<brief_summary>To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL</brief_summary>
	<brief_title>Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1. Patients with active BCLL and with an indication for treatment 2. Age ≥ 18 years 3. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out 1. Any previous treatment for BCLL or any other treatments that can be considered active against BCLL 2. Glucocorticoid unless given in doses ≤ 10 mg /day for other indications than BCLL (e.g. asthma) 3. Known transformation of BCLL 4. Known CNS involvement of BCLL 5. Past or current malignancy, except for: 1. Cervical carcinoma Stage 1B or less 2. Noninvasive basal cell and squamous cell skin carcinoma 3. Malignant melanoma with a complete response of a duration of &gt; 10 years 4. Other cancer diagnoses with a complete response of a duration of &gt; 5 years 6. Chronic or current infectious disease requiring systemic treatment 7. Clinically significant cardiac disease 8. Significant concurrent, uncontrolled medical condition 9. History of significant cerebrovascular disease 10. Known HIV positive 11. Positive serology for hepatitis B, unless due to vaccination 12. Leukapheresis, except as a safety measure before chemotherapy 13. ECOG Performance Status of 3 or 4 14. Patients who at the time of inclusion are not expected to be able to complete the ofatumumabFC regimen 15. Patients who have received treatment with any nonmarketed drug substance or experimental therapy within 4 weeks prior to Visit 1 16. Current participation in any other interventional clinical study 17. Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder) 18. Breast feeding women or women with a positive pregnancy test at Visit 1 19. Women of childbearing potential not willing to use adequate contraception for up to one year after last dose of ofatumumab. Adequate contraception is defined as hormonal birth control or intrauterine device. For patients in the USA the use of a double barrier method is also considered adequate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>B-cell</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>